Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVIGEN(avgn) -- Ignore unavailable to you. Want to Upgrade?

To: SnowShredder who wrote (203)	12/5/2001 5:13:30 PM
From: JMarcus	Respond to of 228

The RAC meeting is tomorrow, Dec. 6th. The minutes of the meeting won't be published in the Federal Register for a couple months. It is my impression that that Avigen won't issue a press release immediately after the RAC meeting, but will wait until either (a) they restart the Coagulin-B liver infusion trial (which they expect to do, once receiving input/guidance from the RAC and/or the FDA) or (b) they meet with the FDA itself approximately 2 weeks after the RAC meeting. If in the next few days, before any press release, we see the stock price start to move, that may be an indication of how well the RAC meeting went, because word is sure to leak out. This could present a good trading opportunity.